A detailed history of State Of Wisconsin Investment Board transactions in Immunovant, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 68,593 shares of IMVT stock, worth $1.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,593
Previous 71,745 4.39%
Holding current value
$1.89 Million
Previous $1.89 Million 0.42%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.51 - $27.51 $86,711 - $86,711
-3,152 Reduced 4.39%
68,593 $1.89 Million
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $510,634 - $643,073
20,344 Added 39.58%
71,745 $1.89 Million
Q1 2024

May 14, 2024

SELL
$30.27 - $43.79 $43,043 - $62,269
-1,422 Reduced 2.69%
51,401 $1.66 Million
Q4 2023

Feb 12, 2024

SELL
$31.31 - $44.19 $199,225 - $281,180
-6,363 Reduced 10.75%
52,823 $2.23 Million
Q3 2023

Nov 14, 2023

SELL
$18.55 - $39.96 $204,606 - $440,758
-11,030 Reduced 15.71%
59,186 $2.27 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $488,934 - $817,760
34,432 Added 96.22%
70,216 $1.33 Million
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $174,765 - $225,695
-11,445 Reduced 24.23%
35,784 $555,000
Q4 2022

Feb 14, 2023

SELL
$6.59 - $17.75 $1.08 Million - $2.92 Million
-164,416 Reduced 77.68%
47,229 $838,000
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $51,569 - $83,587
-13,122 Reduced 5.84%
211,645 $1.18 Million
Q2 2022

Aug 15, 2022

BUY
$3.38 - $5.65 $296,314 - $495,318
87,667 Added 63.94%
224,767 $877,000
Q1 2022

May 13, 2022

BUY
$5.06 - $8.77 $444,267 - $770,006
87,800 Added 178.09%
137,100 $755,000
Q4 2020

Feb 03, 2021

BUY
$36.36 - $52.71 $676,296 - $980,406
18,600 Added 60.59%
49,300 $2.28 Million
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $694,127 - $1.19 Million
30,700 New
30,700 $1.08 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.